Skip to main content
SpringerLink
Log in

Systemic Drugs Used in Dermatology

  • Chapter
  • First Online:
Practical Guide to Dermatology

  • 1350 Accesses

Abstract

In this section, we review systemic medications used in dermatology. We discuss conditions for which they can be used, lab monitoring, common side effects and contraindications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wolverton S. Comprehensive dermatologic drug therapy, 3rd ed. Philadelphia: Elsevier Saunders; 2013.

    Google Scholar 

  2. Bolognia J, Schaffer J, Cerroni L. Dermatology. Philadelphia: Elsevier Saunders; 2017.

    Google Scholar 

  3. Marmor MF, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415–22.

    Google Scholar 

  4. Mohammad S, et al. Examination of hydroxychloroquine use and hemolytic anemia in G6PDH-Deficient patients. Arthritis Care Res (Hoboken). 2018;70(3):481–5.

    CAS  Google Scholar 

  5. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453–60.

    Google Scholar 

  6. Cho HG, et al. Azathioprine and risk of multiple keratinocyte cancers. J Am Acad Dermatol. 2018;78(1): 27–28. e1.

    PubMed  Google Scholar 

  7. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol. 2006;55(3):369–89.

    PubMed  Google Scholar 

  8. Phillips T, et al. Non-Hodgkin’s lymphoma associated with long-term azathioprine therapy. Clin Exp Dermatol. 1987;12(6):444–5.

    CAS  PubMed  Google Scholar 

  9. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol. 1995;131(2):193–7.

    CAS  PubMed  Google Scholar 

  10. Buckley L, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–37.

    PubMed  Google Scholar 

  11. Stathopoulos IP, et al. The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones (Athens). 2011;10(4):280–91.

    Google Scholar 

  12. Reddy S, Ananthakrishnan S, Garg A. A prospective observational study evaluating hypothalamic-pituitary-adrenal axis alteration and efficacy of intramuscular triamcinolone acetonide for steroid-responsive dermatologic disease. J Am Acad Dermatol. 2013;69(2):226–31.

    CAS  PubMed  Google Scholar 

  13. Maza A, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 2):19–27.

    CAS  PubMed  Google Scholar 

  14. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565–81.

    CAS  PubMed  Google Scholar 

  15. Paul CF, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003;120(2):211–6.

    CAS  PubMed  Google Scholar 

  16. Pere AK, et al. Dietary potassium and magnesium supplementation in cyclosporine-induced hypertension and nephrotoxicity. Kidney Int. 2000;58(6):2462–72.

    CAS  PubMed  Google Scholar 

  17. Serratrice J, et al. Interference of dapsone in HbA1c monitoring of a diabetic patient with polychondritis. Diabetes Metab. 2002;28(6 Pt 1):508–9.

    CAS  PubMed  Google Scholar 

  18. Tack CJ, Wetzels JF. Decreased HbA1c levels due to sulfonamide-induced hemolysis in two IDDM patients. Diabetes Care. 1996;19(7):775–6.

    CAS  PubMed  Google Scholar 

  19. Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68(7):1094–9.

    CAS  PubMed  Google Scholar 

  20. Fairris GM, et al. Methotrexate dosage in patients aged over 50 with psoriasis. BMJ. 1989;298(6676):801–2.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Cheng HS, Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis (Auckl). 2018;8:21–9.

    CAS  Google Scholar 

  22. Khan S, Subedi D, Chowdhury MM. Use of amino terminal type III procollagen peptide (P3NP) assay in methotrexate therapy for psoriasis. Postgrad Med J. 2006;82(967):353–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Gutierrez JC, Hwang K. The toxicity of methotrexate in male fertility and paternal teratogenicity. Expert Opin Drug Metab Toxicol. 2017;13(1):51–8.

    CAS  PubMed  Google Scholar 

  24. Cudmore J, et al. Methotrexate and trimethoprim-sulfamethoxazole: toxicity from this combination continues to occur. Can Fam Physician. 2014;60(1):53–6.

    PubMed  PubMed Central  Google Scholar 

  25. Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother. 1992;26(2):234–7.

    CAS  PubMed  Google Scholar 

  26. Colebatch AN, Marks JL, Edwards CJ. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev. 2011;11:CD008872.

    Google Scholar 

  27. Hewitt RJ, et al. Screening tests for tuberculosis before starting biological therapy. BMJ. 2015;350:h1060.

    PubMed  Google Scholar 

  28. Dobler CC. Biologic agents and tuberculosis. Microbiol Spectr 2016;4(6).

    Google Scholar 

  29. Bavinck JN, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol. 1995;13(8):1933–8.

    CAS  PubMed  Google Scholar 

  30. DiGiovanna JJ. Retinoid chemoprevention in the high-risk patient. J Am Acad Dermatol. 1998;39(2 Pt 3):S82–5.

    CAS  PubMed  Google Scholar 

  31. DiGiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol. 2001;45(5):S176–82.

    CAS  PubMed  Google Scholar 

  32. Gniadecki R, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol. 2007;157(3):433–40.

    CAS  PubMed  Google Scholar 

  33. Sherman SI, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med. 1999;340(14):1075–9.

    CAS  PubMed  Google Scholar 

  34. Hansen TJ, et al. Standardized laboratory monitoring with use of isotretinoin in acne. J Am Acad Dermatol. 2016;75(2):323–8.

    CAS  PubMed  Google Scholar 

  35. Chivot M. Acne flare-up and deterioration with oral isotretinoin. Ann Dermatol Venereol. 2001;128(3 Pt 1):224–8.

    CAS  PubMed  Google Scholar 

  36. Menter A, Strober B, Kaplan DH, Kivelevitch D, et al. Guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol In preparation.

    Google Scholar 

  37. Ou Z, et al. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis. Int Immunopharmacol. 2018;54:303–10.

    CAS  PubMed  Google Scholar 

  38. Wollenberg A, et al. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018;6(5):778–1780. e1.

    PubMed  Google Scholar 

  39. Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018;154(10):1208–11.

    PubMed  PubMed Central  Google Scholar 

  40. Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2018;78(1):62–69. e1.

    PubMed  Google Scholar 

  41. Menter A, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–15.

    PubMed  Google Scholar 

  42. Gordon K, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241–51.

    CAS  PubMed  Google Scholar 

  43. Paradisi A, et al. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014;71(2):278–83.

    CAS  Google Scholar 

  44. Papp KA, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304–12.

    CAS  PubMed  Google Scholar 

  45. Reich K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–74.

    CAS  PubMed  Google Scholar 

  46. Menter A, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31. e1–15.

    Google Scholar 

  47. Afif W, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(5):1133–9.

    CAS  PubMed  Google Scholar 

  48. Gottlieb A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633–40.

    CAS  PubMed  Google Scholar 

  49. Leonardi CL, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–74.

    CAS  Google Scholar 

  50. Emer JJ, Frankel A, Zeichner JA. A practical approach to monitoring patients on biological agents for the treatment of psoriasis. J Clin Aesthet Dermatol. 2010;3(8):20–6.

    PubMed  PubMed Central  Google Scholar 

  51. Blauvelt A, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17.

    CAS  PubMed  Google Scholar 

  52. Gomez-Garcia F, et al. Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. Br J Dermatol. 2017;176(3):594–603.

    CAS  PubMed  Google Scholar 

  53. Gordon KB, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–56.

    CAS  PubMed  Google Scholar 

  54. van de Kerkhof PC, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98. e4.

    Google Scholar 

  55. Langley RG, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38.

    PubMed  Google Scholar 

  56. Liu LY, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017;77(4): 675–682. e1.

    PubMed  PubMed Central  Google Scholar 

  57. Papp KA, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016;74(5):841–50.

    CAS  PubMed  Google Scholar 

  58. Bayart CB, et al. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017;77(1):167–70.

    PubMed  Google Scholar 

  59. Bissonnette R, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175(5):902–11.

    CAS  PubMed  Google Scholar 

  60. Mackay-Wiggan J, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790.

    PubMed  PubMed Central  Google Scholar 

  61. Rothstein B, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017;76(6):1054–1060. e1.

    PubMed  Google Scholar 

  62. Plovanich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol. 2015;151(9):941–4.

    PubMed  Google Scholar 

  63. Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M. Spironolactone use and the risk of breast cancer. J Am Acad Dermatol. 2016:AB72.

    Google Scholar 

  64. Oliveira-Soares R, et al. Finasteride 5 mg/day treatment of patterned hair loss in normo-androgenetic postmenopausal women. Int J Trichology. 2013;5(1):22–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Danesh M, Murase JE. Increasing utility of finasteride for frontal fibrosing alopecia. J Am Acad Dermatol. 2015;72(6):e157.

    PubMed  Google Scholar 

  66. Zakhem GA, Motosko CC, Mu EW, Ho RS. Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review. J Am Acad Dermatol. 2019;80(4):957–69.

    PubMed  Google Scholar 

  67. D’Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol. 2007;8(1):21–5.

    PubMed  Google Scholar 

  68. Wilt TJ, et al. Five-alpha-reductase Inhibitors for prostate cancer prevention. Cochrane Database Syst Rev. 2008(2);CD007091.

    Google Scholar 

  69. Ekelem C, et al. Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: a systematic review. JAMA Dermatol. 2018.

    Google Scholar 

  70. Chen AC, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015;373(17):1618–26.

    CAS  PubMed  Google Scholar 

  71. Trouvin AP, et al. Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study. Clin Exp Immunol. 2015;180(1):11–8.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Henry Ford Health System, 3031 West Grand Blvd, Suite 800, Detroit, MI, 48202, USA

    Ellen N. Pritchett

  2. Department of Dermatology, Henry Ford Health System, 3031 West Grand Blvd, Suite 800, Detroit, MI, 48202, USA

    Karlee Novice

Authors
  1. Karlee Novice
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ellen N. Pritchett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ellen N. Pritchett .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Henry Ford Health System, Detroit, MI, USA

    Henry W. Lim

  2. Department of Dermatology, Henry Ford Health System, Detroit, MI, USA

    Laurie L. Kohen

  3. Department of Dermatology, Henry Ford Health System, Detroit, MI, USA

    Samantha L. Schneider

  4. Department of Dermatology, Henry Ford Health System, Detroit, MI, USA

    Danielle Yeager

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Novice, K., Pritchett, E.N. (2020). Systemic Drugs Used in Dermatology. In: Lim, H., Kohen, L., Schneider, S., Yeager, D. (eds) Practical Guide to Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-18015-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-18015-7_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-18014-0

  • Online ISBN: 978-3-030-18015-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation